By Jeff Overley ( September 2, 2015, 12:36 PM EDT) -- A divided Federal Circuit on Wednesday rejected Amgen Inc.'s bid to block sales of Sandoz Inc.'s biosimilar Zarxio during continued litigation between the companies, clearing the way for the first biosimilar approved under the Biologics Price Competition and Innovation Act....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.